Posted by AGORACOM-JC
at 4:00 PM on Tuesday, February 25th, 2020
At a time when Cannabis stocks are struggling and in a massive state of flux, due to an inability to actually deliver real businesses, Hollister Biosciences (HOLL:CSE) has been quietly building a real business, products, revenue and customers in 220 of California’s 600 dispensaries …. and growing, including California’s #1 hash infused pre-roll “Hashbone”.
In addition to that, Hollister has also signed LOI’s, JV’s and licensing deals with major partners with massive nationwide and even global audiences launching in the next couple of months. We’ll save details of those for another day but suffice it to say one of those partners is the world renowned Tommy Chong (of Cheech & Chong) who stated:
“I only partner with the best-in-class companies and I am really pleased to have the Hollister Cannabis Co. bring their amazing Tommy Chong’s Cannabis™ Full Spectrum Elixir to the market for me”.
If that was all Hollister had going, they’d be in great shape with a super bright future and better than most Cannabis companies (small and large) who can’t even get product out the door.
BUT THERE’S MORE – THE $20,000,000 ACQUISITION THAT COMES WITH $CDN 16.4M REVENUE & $CDN 2.48M EBITDA
Earlier today, Hollister announced an LOI to acquire Venom Extracts, one of Arizona’s largest producers of Award-Winning Medical Cannabis Distillate. Just how good is Venom? In 2019, Venom generated $CDN 16.4M in revenue and $CDN 2.48M EBITDA in 2019 (subject to due diligence confirmation) … and all of that was just from the state of Arizona! Venom CEO Mason Cave and his team have aggressive plans to expand its brand and success into other states, including California as it benefits from Hollister’s distribution into 220 dispensaries. Â
If you think “growth talk is cheap” (which is often the case), consider the fact that 30% of Venom’s $20,000,000 sale price kicks in if/when revenues hit $CDN 30,000 and $CDN 40,000 …. by December 31, 2021. In my experience, companies joining forces don’t include such terms if there isn’t a reasonable expectation for hitting those numbers. It doesn’t guarantee it but you can bet they have good reason to believe Venom sales will get to one or both of those numbers in just 21 months from now.
If you’re looking for Cannabis companies that are going to survive and thrive over this next decade, then grab your favourite beverage and watch this interview with Hollinger President, Alex Somjen.
We loved what we heard and look forward to your feedback in Hollister’s CEO Verified Forum below!
Posted by AGORACOM-JC
at 6:10 AM on Tuesday, February 25th, 2020
Company intends to utilize its database of 165,000 patients to further psilocybin research, develop new products and partner with global leaders in the field
“Empower is uniquely positioned to immediately impact research, develop new products and bring advancements to plant-based therapies, under a framework of rapidly increasing awareness and a movement toward decriminalization of psychedelic treatment options.” said Steven McAuley, Chairman & CEO of Empower
VANCOUVER, BC / February 25, 2020 / EMPOWER CLINICS INC.(CSE:CBDT)(OTC:EPWCF)(Frankfurt:8EC) (“Empower” or the “Company“), a vertically integrated and growth-oriented life sciences company is pleased to announce it intends to leverage its existing clinic network, the developing franchise brand, its 165,000 patients and product development capability, to create psilocybin and psychedelics subsidiaries.
The Company has been conducting market research on advancements in
psilocybin and psychedelics in North America and globally, along with
building the business case internally on how to create greater
shareholder value, utilizing Company assets that include clinics,
patients, physicians and technology.
“There is an undeniable mental health crisis in our country and
around the world, that has an ever-increasing, devastating affect on our
society.” said Steven McAuley, Chairman & CEO of Empower. “Empower
is uniquely positioned to immediately impact research, develop new
products and bring advancements to plant-based therapies, under a
framework of rapidly increasing awareness and a movement toward
decriminalization of psychedelic treatment options.”
Studies conducted by nationally and internationally recognized
medical institutions indicate that psilocybin has shown efficacy,
tolerability, and safety in the treatment of a variety of mental health
conditions, including but not limited to addiction, depression, anxiety
disorders, and end-of-life psychological distress.
“Over the past seven years, we have assisted over one hundred
thousand patients obtain access to alternative health care and medicinal
cannabis. The provision of legal access to psilocybin therapies are
perfectly in-line with our philosophy of providing a Scientific Approach
to Alternative Medicine™“, said Dustin Klein, SVP
Business Development and Director, Empower Clinics Inc. “Clinical trials
have shown that psilocybin therapies provide tremendous help with
conditions we see everyday in our clinics. It is our responsibility, to
make sure we are providing the most up-to-date alternative therapies to
our patients and our community.”
The mental health crisis could cost the world $16 trillion by 2030
and according to Future Market Insights; the global behavioral health
(non-pharmacological) market is expected to be valued at US$156 billion
by 2028.
The United States Food and Drug Administration has determined that
preliminary clinical evidence indicates psilocybin may demonstrate
substantial improvement over other available therapies for
treatment-resistant depression; and granted a Breakthrough Therapy
designation for a treatment that uses psilocybin as a therapy for such
depression.
The Company also announces it has issued to Haywood Securities Inc.,
4,000,000 common shares of the Company (the “Work Fee Shares”) under the
financial advisory agreement dated September 25, 2019 (the “Agreement”)
based on Haywood Securities Inc. completing the final written SWOT
analysis. The shares issued are priced at fair market value of the
common shares of the Corporation as at the date of issuance of the Work
Fee Shares.
ABOUT EMPOWER
Empower is a vertically-integrated health & wellness brand with
it’s first hemp-derived CBD extraction facility under development, the
Company produces its proprietary line of cannabidiol (CBD) based
products and distributes products through company owned and franchised
clinics, with wholesale partnerships, online channels and with new
retail opportunities nationwide in the U.S. The company is a leading
multi-state operator of a network of physician-staffed wellness clinics,
focused on helping patients improve and protect their health, through
innovative physician recommended treatment options. The Company has
commenced activity on how to connect its significant data, to the
potential of the efficacy of alternative treatment options related to
hemp-derived cannabidiol (CBD) therapies, psilocybin and other
psychedelic plant-based treatment options.
ON BEHALF OF THE BOARD OF DIRECTORS:
Steven McAuley Chief Executive Officer
CONTACTS:
Investors: Steven McAuley Chairman & CEO [email protected] 604-789-2146
Investors: Dustin Klein SVP, Business Development [email protected] 720-352-1398
For French inquiries: Remy Scalabrini, Maricom Inc., E: [email protected], T: (888) 585-MARI
DISCLAIMER FOR FORWARD-LOOKING STATEMENTS
This news release contains certain “forward-looking statements”
or “forward-looking information” (collectively “forward looking
statements”) within the meaning of applicable Canadian securities laws.
All statements, other than statements of historical fact, are
forward-looking statements and are based on expectations, estimates and
projections as at the date of this news release.Forward-looking statements
can frequently be identified by words such as “plans”, “continues”,
“expects”, “projects”, “intends”, “believes”, “anticipates”,
“estimates”, “may”, “will”, “potential”, “proposed” and other similar
words, or information that certain events or conditions “may” or “will”
occur. Forward-looking statements in this news release include
statements regarding; the Company’s intention to create psilocybin and
psychedelics divisions, that market research on advancements in
psilocybin and psychedelics in North America and globally will create
greater shareholder value, the Company’s intention to open a hemp-based
CBD extraction facility, the expected benefits to the Company and its
shareholders as a result of the proposed acquisitions and partnerships;
the effectiveness of the extraction technology; the expected benefits
for Empower’s patient base and customers; the benefits of CBD based
products; the effect of the approval of the Farm Bill; the growth of the
Company’s patient list and that the Company will be positioned to be a
market-leading service provider for complex patient requirements in 2019
and beyond. Such statements are only projections, are based on
assumptions known to management at this time, and are subject to risks
and uncertainties that may cause actual results, performance or
developments to differ materially from those contained in the
forward-looking statements, including; that the Company may not open a
hemp-based CBD extraction facility; that legislative changes may have an
adverse effect on the Company’s business and product development; that
the Company may not be able to obtain adequate financing to pursue its
business plan; general business, economic, competitive, political and
social uncertainties; failure to obtain any necessary approvals in
connection with the proposed acquisitions and partnerships; and other
factors beyond the Company’s control. No assurance can be given that any
of the events anticipated by the forward-looking statements will occur
or, if they do occur, what benefits the Company will obtain from them.
Readers are cautioned not to place undue reliance on the forward-looking
statements in this release, which are qualified in their entirety by
these cautionary statements. The Company is under no obligation, and
expressly disclaims any intention or obligation, to update or revise any
forward-looking statements in this release, whether as a result of new
information, future events or otherwise, except as expressly required by
applicable laws.
SOURCE: Empower Clinics Inc.
Tags: CSE, Hemp, Marijuana, small cap stocks, stocks, tsx, tsx-v Posted in Empower Clinics Inc. | Comments Off on Empower Clinics $CBDT.ca to Create #Psilocybin and Psychadelics Division Leveraging Corporate Wellness Clinics and Franchise Clinic Network $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca
Posted by AGORACOM-JC
at 6:02 AM on Tuesday, February 25th, 2020
Company signed a Letter of Intent to acquire Venom Extracts
One of Arizona’s premier extract brands and one of the state’s largest producers of award-winning medical cannabis distillate and related products.
Venom Extracts reports having generated CDN$ 16.4 million in revenue and CDN$ 2.48 million in EBIDTA from its product line of Cannabis Concentrates, P.H.O Concentrates and Cartridges.
Hollister Biosciences Inc., the creator of California’s #1 hash-infused pre-roll HashBone, enters into Letter of Intent to acquire Venom Extracts, one of Arizona’s largest producers of award-winning medical cannabis distillate and related products
VANCOUVER, Feb. 25, 2020 – Hollister Biosciences Inc.(CSE: HOLL, FRANKFURT: HOB, OTC: HSTRF) (the “Company” or “Hollister“) – a vertically integrated cannabis branding company with products in 220 dispensaries throughout California, is pleased to announce that the Company signed a Letter of Intent (“LOI“) on February 20th, 2020 to acquire Venom Extracts ( “Venom“), one of Arizona’s premier extract brands and one of the state’s largest producers of award-winning medical cannabis distillate and related products.
HIGHLY ACCRETIVE $20,000,000 ACQUISITION
For the year ended December 31, 2019, Venom Extracts reports having generated CDN$ 16.4 million in revenue and CDN$ 2.48 million in EBIDTA from its product line of Cannabis Concentrates, P.H.O Concentrates and Cartridges. Hollister
cautions that revenue and EBITDA figures have not yet been audited and
are based on reports prepared by Venom management. Though Hollister believes the figures to be highly reliable, their audit will be part of the due diligence before closing.
The all stock purchase price is anticipated to be CDN$ 20,000,000, with 70% to be paid upfront and 30% to be paid upon milestone achievements. The acquisition is expected to close by March 31, 2020 subject to normal course due diligence.
“Venom has established itself as a leading extraction operation with a prominent brand in the Arizona marketplace”, said Carl Saling,
Founder and CEO of Hollister Biosciences Inc. “We feel this
acquisition will present a great deal of opportunity for synergy between
Hollister and Venom, providing avenues for both companies into the Arizona, California
and additional marketplaces for cannabis products. Venom Extracts has a
highly skilled and experienced management team with a track record for
operational excellence. This transaction is highly accretive and
represents a fundamental part of the future growth of both companies.”
LOI TERMS
The terms of the LOI, which will be formalized by a definitive agreement on closing, are as follows:
The Company will acquire Venom Extracts for CDN$20,000,000 with such payment to be issued in Hollister common stock (the “Payment Shares“)
The stock price will be determined based on the greater of:
The 14-day VWAP (Volume Weighted Average Price) capped at $0.25 subsequent to announcing the transaction and $0.20
Once the share price is established, 70% of the Payment Shares will
be issued upon closing of the transaction, subject to hold periods.
The remaining 30% of the Payment Shares will be issued when and if the following milestones have been met on or prior to December 31st, 2021:
20% (of the total number of Payment Shares) will be issued when revenue of Venom Extracts reaches CDN$ 30,000,000 (calculated in accordance with IFRS from January 1, 2020).
10% (of the total number of Payment Shares) will be issued when revenue of Venom Extracts reaches CDN$ 40,000,000(calculated in accordance with IFRS from January 1, 2020).
“We are very pleased to be entering into this transaction with Hollister”, shared Mason Cave,
CEO of Venom Extracts. “The opportunities for resource and capability
sharing between the two companies are plentiful. This also represents a
more expeditious avenue for us into the large and rapidly growing California marketplace. Hollister
has an excellent management team in place and has established itself as
a sought-after brand house of popular cannabis and hemp products in
California. We feel that our contribution on the extraction side will
help diversify Hollister’s product offering and continue to
build out the brand equity of both companies across multiple state and
eventually global marketplaces”
In association with the arm’s length transaction, Hollister
will not be assuming any long-term debt, a new control position will be
created and there is no change in Management, or the Board of Directors
of Hollister being contemplated at this time.
Finder’s fees will be payable in accordance with the policies of the Canadian Securities Exchange.
About Hollister Biosciences Inc.
Hollister Biosciences Inc. is a vertically integrated cannabis
company with multiple, high-quality products now carried in 220 of Indus
Holdings (CSE: INDS), Hollister’s
exclusive distribution partner’s 600 dispensaries. This level of
penetration is expected to grow as the Company accelerates its seed to
shelf, high margin business and product development model.
Capitalizing on this success, Hollister’s vision is to
become the sought-after premium brand portfolio of innovative, high
quality cannabis across multiple states and hemp products nationwide.
Our wholly owned California subsidiary, Hollister Cannabis Co, is the 1st state and locally licensed Cannabis Company in the City of Hollister, California,
the birthplace of the “American Biker” from which we embrace the outlaw
roots of Hollister to drive our Company fearlessly down the road of
success.
Products from Hollister Cannabis Co. include HashBone, the brand’s
premier artisanal hash-infused pre-roll ranked as California’s #1 hash
infused pre-roll, along with solvent-free bubble hash, pre-packaged
flower, pre-rolls, tinctures, vape products, and full-spectrum high CBD
pet tinctures.
Venom Extracts is one of Arizona’s premier extract
brands and one of the state’s largest producers of award-winning medical
cannabis distillate and related products. With an experienced
management team and unparalleled reputation for quality, Venom Extracts
prides itself as a differentiated extraction company by producing legal
Marijuana products at a price point that allows retailers to generate
higher profits. Focused on proprietary efficiencies, the Company is
able to produce more product per square foot than its competition,
maintaining lower costs and risks than a typical extraction company. The
company’s expansion strategy is centered on entering new markets/states
that are approved for medical cannabis use and/or approved or have a
reasonable expectation to be approved for recreational use in the near
future.
Neither the Canadian Securities Exchange nor its Market Regulator
(as that term is defined in the policies of the Canadian Securities
Exchange) accepts responsibility for the adequacy or accuracy of this
release.
Forward-Looking Information: This news release includes certain
statements that may be deemed “forward-looking statements”. The use of
any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”,
“will”, “would”, “project”, “should”, “believe” and similar expressions
are intended to identify forward-looking statements. Although the
Company believes that the expectations and assumptions on which the
forward-looking statements are based are reasonable, undue reliance
should not be placed on the forward-looking statements because the
Company can give no assurance that they will prove to be correct. Since
forward-looking statements address future events and conditions, by
their very nature they involve inherent risks and uncertainties. These
statements speak only as of the date of this News Release. Actual
results could differ materially from those currently anticipated due to a
number of factors and risks including various risk factors discussed in
the Company’s disclosure documents which can be found under the
Company’s profile onwww.sedar.com
Tags: Cannabis, CSE, Hemp, Marijuana, stocks, tsx, tsx-v Posted in Featured, Hollister Biosciences | Comments Off on Hollister Biosciences $HOLL.ca Signs Letter of Intent to Acquire Venom Extracts With $16.4 Million In Revenue And $2.48 Million EBITDA $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca $FAF.ca
Posted by AGORACOM-JC
at 4:03 PM on Monday, February 24th, 2020
In 1948, Winston Churchill said, “Those who fail to learn from history are condemned to repeat it”. Unfortunately, many Cannabis companies aren’t historians and are repeating the dot-com to dot-bomb cycle of raising tons of money but no clue how to build a real business with it.
You know what else we learned from that cycle? Web 2.0 was the birth of companies with real business plans, products, customers and revenues. They went on to dominate the next 20 years.
Enter MOTA Ventures (MOTA:CSE), who has become a leader in online CBD sales into the North American market, thanks to an e-commerce “engine” built by CEO Ryan Hoggan and his team over the past few years at Unified Funding. That engine is so powerful that is has racked up over $200 MILLION in sales from over 1 million paying customers over a number of products, including CBD sales of $25 MILLION by “First Class CBD”, which was acquired by MOTA for $32 MILLION.
The best part for MOTA shareholders? Ryan is highly motivated to continue with his successful ways because Unified Funding can earn an additional $15 MILLION if First Class CBD achieves sales of $62 MILLION. In my experience, companies don’t put bonuses into contracts unless they both believe there is a reasonable belief they can be achieved. Will he hit $62M? Or fall short at the other 2 milestones of $52M and $42M?
Watch this interview and you be the judge. Either way, MOTA shareholders should get their popcorn ready because Ryan has already proven he’s leading MOTA into the Cannabis 2.0 phase. Success is already here, now its just a question of how high MOTA will fly.
Watch this interview and share it with every investor you know!
Posted by AGORACOM-JC
at 9:15 AM on Monday, February 24th, 2020
Announced the appointment of Jeffrey Stoss as Chief Financial Officer of the Company.
Mr. Stoss brings more than 17 years of finance experience to his role at NORTHBUD, with a particular specialty in high-growth environments.
TORONTO, Feb. 24, 2020 — North Bud Farms Inc. (CSE: NBUD) (OTCQB: NOBDF) (“NORTHBUD” or the “Company“) is pleased to announce the appointment of Jeffrey Stoss as Chief Financial Officer of the Company.
“We are pleased to welcome Jeff to our dynamic team as NORTHBUD is at
an exciting time in its development,†stated Sean Homuth, CEO of North
Bud Farms Inc. “Jeff brings specialty experience in accounting and
finance having worked with and advised many public companies over the
years in both Canada and the United States. His leadership and expertise
will be essential in executing our strategic plan and taking the
Company to its next level of growth.â€
Mr. Stoss brings more than 17 years of finance experience to his role
at NORTHBUD, with a particular specialty in high-growth environments.
He is the co-founder and Chief Operating Officer of the outsourced
finance services firm, Positive Venture Group Inc. He has previously
served as CFO for publicly-traded companies and technology start-ups.
Mr. Stoss has professional accountant designations in both Canada and
the United States.
RSU Grants
On February 20, 2020, the Company’s board of directors approved the
grant of 361,000 restricted share units (“RSUsâ€) to certain directors
and consultants of the Company. The RSUs vest in four equal tranches
starting three months from the date of grant. Each vested RSU entitles
the holder thereof to receive one common share of the Company upon
delivery of an exercise notice, in accordance with the Omnibus Plan.
About North Bud Farms Inc.
NORTHBUD, through its U.S. subsidiary Bonfire Brands USA, has
acquired cannabis production facilities in California and Nevada. The
Salinas, California 11-acre farm is actively cultivating cannabis in its
60,000 sq. ft. of licensed greenhouse production space. The Reno,
Nevada property is located on 3.2 acres of land which was acquired
through the acquisition of Nevada Botanical Science, Inc., a world class
cannabis production, research and development facility with 5,000 sq.
ft. of indoor cultivation which holds medical and adult use licenses for
cultivation, extraction and distribution. Through its wholly-owned
Canadian subsidiary, GrowPros MMP Inc., the Company is pursuing a
license under The Cannabis Act, to cultivate in its state-of-the-art
purpose-built cannabis production facility located on 135 acres of
agricultural land in Low, Quebec, Canada.
Neither the CSE nor its Regulation Services Provider (as that term is
defined in the policies of the CSE) accepts responsibility for the
adequacy or accuracy of this release.
Forward-looking statements Certain
statements and information included in this press release that, to the
extent they are not historical fact, constitute forward-looking
information or statements (collectively, “forward-looking statementsâ€)
within the meaning of applicable securities legislation.
Forward-looking statements, include but are not limited to those
identified by the expressions “anticipateâ€, “believeâ€, “planâ€,
“estimateâ€, “expectâ€, “intendâ€, “mayâ€, “should†and similar expressions
to the extent they relate to the Company or its management.
Forward-looking statements, including those regarding the success of
the Company’s licence application, the Company’s ability to execute its
strategic plan, conditions in the cannabis market, the Company entering
agreements in connection with the B2B supply of cannabis and the
Company’s transition into a revenue-generating operational phase of
development are based on the reasonable assumptions, estimates, analysis
and opinions of management made in light of its experience and its
perception of trends, current conditions and expected developments, as
well as other factors that management believes to be relevant and
reasonable in the circumstances at the date that such statements are
made, but which may prove to be incorrect.
Forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause the actual results,
performance or achievements of the Company to differ materially from any
future results, performance or achievements expressed or implied by the
forward-looking statements. Such risks and uncertainties include,
among others, the risk factors included in the Company’s final long form
prospectus dated August 21, 2018, which is available under the
Company’s SEDAR profile at www.sedar.com.
Accordingly, readers should not place undue reliance on any such
forward-looking statements. Further, any forward-looking statement
speaks only as of the date on which such statement is made. New factors
emerge from time to time, and it is not possible for the Company’s
management to predict all of such factors and to assess in advance the
impact of each such factor on the Company’s business or the extent to
which any factor, or combination of factors, may cause actual results to
differ materially from those contained in any forward-looking
statements. The Company does not undertake any obligation to update any
forward-looking statements to reflect information, events, results,
circumstances or otherwise after the date hereof or to reflect the
occurrence of unanticipated events, except as required by law including
securities laws. This news release does not constitute an offer to sell
or a solicitation of any offer to buy any securities of the Company.
FOR ADDITIONAL INFORMATION, PLEASE CONTACT: North Bud Farms Inc. Edward Miller VP, IR & Communications Office: (855) 628-3420 ext. 3 [email protected]
Tags: Cannabis, CBD, CSE, Hemp, Marijuana, stocks Posted in North Bud Farms Inc | Comments Off on North Bud Farms $NBUD.ca Announces the Appointment of Jeffrey Stoss as Chief Financial Officer $CGC $ACB $APH $CRON.ca $OGI.ca
Posted by AGORACOM-JC
at 7:34 AM on Saturday, February 22nd, 2020
Announced a transition after the definitive close of First Class CBD acquisition
Appointed Ryan Dean Hoggan to Chief Executive Officer
Acquisition of First Class CBD coupled with the upcoming U.S. roll out of the Company’s European CBD brand, Sativida, made the appointment of Mr. Hoggan to Chief Executive Officer a natural fit
Mr. Hoggan brings more than 18 years of leadership, global business development and entrepreneurship experience in the health equipment, medical devices and natural health products sectors
VANCOUVER, BC / February 22, 2020 / Mota Ventures Corp. (CSE:MOTA)(FSE:1WZ:GR)(OTC:PEMTF) (the “Company” or “Mota“) is pleased to announce a transition after the definitive close of First Class CBD acquisition, the Company’s Board of Directors has appointed Ryan Dean Hoggan to Chief Executive Officer. The acquisition of First Class CBD coupled with the upcoming U.S. roll out of the Company’s European CBD brand, Sativida, made the appointment of Mr. Hoggan to Chief Executive Officer a natural fit. Ryan brings a wealth of expertise to this role, being one of the founders of Unified Funding LLC and First Class CBD. Ryan is an experienced strategist, with a strong understanding of building high value consumer brands with significant annual revenue. Ryan’s extensive background in the online e-commerce space will continue to drive the Company’s rapid growth in the US and spearhead its expansion into the European market. The Company intends to continue its roll up strategy of acquiring profitable, well-known CBD brands globally.
Mr. Hoggan brings more than 18 years of leadership, global business
development and entrepreneurship experience in the health equipment,
medical devices and natural health products sectors. Early in his
career, Ryan took on a leadership role in his family business, HOGGAN
Health Industries, where he led operations, business development and
marketing efforts. After identifying an untapped niche in the market, he
founded Hoggan Medical where he went on to launch over 100 health,
fitness and medical device products and negotiated contracts with big
and small customers including the Mayo Clinic, Boeing, Daimler AG and
the Los Angeles Lakers (NBA).
In 2014, Ryan discovered the power of CBD and essential oils – both
personally and professionally – after a personal health scare prompted
him to research and subsequently try holistic products to improve his
health. The experience ultimately led him to become a Partner and
President of Offer Space, LLC and Real Oil, LLC, two rapidly growing
E-commerce and technology companies focused on serving U.S. based and
international consumers in the CBD and natural health products market.
In June 2019, Mr. Hoggan led a strategic divestiture of the businesses
to Unified Funding, LLC to help continue an impressive growth trend.
Through the operations of Unified Funding, LLC, the business has
generated a database of over 4.5 million customer records and
facilitated over $200 million in consumer transactions from more than
one million paying customers in sectors such as beauty, nutrition and
CBD products.
Mr. Hoggan holds a Bachelor of Business Administration (BBA) from
Westminster College, an MBA from The University of Arizona and a Master
of Global Management (MGM) from the Thunderbird School of Global
Management at Arizona State University.
In connection with Ryan’s appointment to CEO, Joel Shacker will
transition to the role of President of the Company and will remain a
member of the board of directors.
“I am very excited to take on the CEO role at Mota and focus the
operations on becoming a global E-commerce CBD company. I am also
excited about the partnership between Unified and Sativida. Unified’s
extensive experience in the U.S. and strong logistics and supply chain
will provide significant support for the launch of the Sativida line in
the U.S. I believe through the direct-to-consumer online platforms we
will become a leader in the CBD space. We plan to aggressively expand
First Class’s existing operations in the U.S. as well as launch a
European expansion, which we anticipate will yield similar results to
our U.S. operations last year,” stated Ryan Hoggan, CEO of the Company.
“We are extremely happy to have someone with Ryan’s extensive
experience stepping into this role. I am confident in his ability to
execute on expanding operations and generating further revenue. I look
forward to continuing to build the Company in my new role as President
and to working with Ryan during his transition to CEO of Mota.” stated
Joel Shacker.
About Mota Ventures Corp.
Mota is seeking to become a vertically integrated global CBD brand.
Its plan is to cultivate and extract CBD into high-quality value-added
products from its Latin American operations and distribute it both
domestically and internationally. Its existing operations in Colombia
consist of a 2.5-hectare site that has optimal year-round growing
conditions and access to all necessary infrastructure. Mota is looking
to establish sales channels and a distribution network internationally
through the acquisition of the Sativida and First Class CBD brands. Low
cost production, coupled with international, direct to customer sales
channels will provide the foundation for the success of Mota.
ON BEHALF OF THE BOARD OF DIRECTORS
MOTA VENTURES CORP. Joel Shacker
President
For further information, readers are encouraged to contact Joel Shacker, President & CEO at +604.423.4733 or by email at [email protected] or www.motaventuresco.com
Neither the Canadian Securities Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the Canadian
Securities Exchange) accepts responsibility for the adequacy or accuracy
of this press release, which has been prepared by management.
All statements in this press release, other than statements of
historical fact, are “forward-looking information” with respect to the
Company within the meaning of applicable securities laws, including with
respect to the Company’s rapid growth in the US and expansion into the
European market,its plans to become a vertically
integrated global CBD brand, its plans to cultivate and extract cannabis
to produce CBD and high-quality value added CBD products in Latin
America for distribution domestically and internationally and its plans
to acquire revenue-producing CBD brands and operations in Europe and
North America. The Company provides forward-looking statements for the
purpose of conveying information about current expectations and plans
relating to the future and readers are cautioned that such statements
may not be appropriate for other purposes. By its nature, this
information is subject to inherent risks and uncertainties that may be
general or specific and which give rise to the possibility that
expectations, forecasts, predictions, projections or conclusions will
not prove to be accurate, that assumptions may not be correct and that
objectives, strategic goals and priorities will not be achieved. These
risks and uncertainties include but are not limited those identified and
reported in the Company’s public filings under the Company’s SEDAR
profile at www.sedar.com. Although the Company has attempted to identify
important factors that could cause actual actions, events or results to
differ materially from those described in forward-looking information,
there may be other factors that cause actions, events or results not to
be as anticipated, estimated or intended. There can be no assurance that
such information will prove to be accurate as actual results and future
events could differ materially from those anticipated in such
statements. The Company disclaims any intention or obligation to update
or revise any forward-looking information, whether as a result of new
information, future events or otherwise unless required by law.
SOURCE: Mota Ventures Corp.
Tags: Cannabis, CSE, Hemp, Marijuana, stocks, tsx, tsx-v, weed Posted in Featured, Mota Ventures Corp. | Comments Off on Mota Ventures $MOTA.ca Announces Transition After Definitive Close of First Class #CBD Acquisition; Ryan Hoggan is New CEO $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca $FAF.ca
Posted by AGORACOM-JC
at 11:30 AM on Friday, February 21st, 2020
SPONSOR: CardioComm Solutions (EKG: TSX-V)
– The heartbeat of cardiovascular medicine and telemedicine. Patented
systems enable medical professionals, patients, and other healthcare
professionals, clinics, hospitals and call centres to access and manage
patient information in a secure and reliable environment.
M-Health Device Market is Booming Worldwide
Mhealth field has emerged as a sub-segment of eHealth, the use of information and communication technology (ICT), such as computers, mobile phones, communications satellite, patient monitors, etc., for health services and information.
According to an analyst firm, around 2.8 million patients worldwide were using a home monitoring service based on equipment with integrated connectivity
By Orian Research on February 21, 2020
According to a Latest market research report titled, ‘M-Health Device
Market’, added on Orian Research. The report has been processed on the
basis of a comprehensive analysis with inputs from industry experts. The
report presents the market scenario and its potential growth prospects
during the forecast period. The report also presents the evaluation of
the competitive landscape of the market. The leading strategies,
collaborations, innovations, and market revenue of the major players has
been elaborated in this report. The approvals and insights on the top
companies prevalent in the market will enable the reader to get
accustomed with the market opportunities that they can tackle with
informed and favorable business strategies
mHealth is an abbreviation for mobile health, a term used for the
practice of medicine and public health supported by mobile devices. The
term is most commonly used in reference to using mobile communication
devices, such as mobile phones, tablet computers and PDAs, and wearable
devices such as smart watches, for health services, information, and
data collection. The mHealth field has emerged as a sub-segment of
eHealth, the use of information and communication technology (ICT), such
as computers, mobile phones, communications satellite, patient
monitors, etc., for health services and information.
According to an analyst firm, around 2.8 million patients worldwide
were using a home monitoring service based on equipment with integrated
connectivity at the end of 2013. The figure does not include patients
that use monitoring devices connected to a PC or mobile phone. It only
includes systems that rely on monitors with integrated connectivity or
systems that use monitoring hubs with integrated cellular or fixed-line
modems.
Global M-Health Device Industry 2020 Market Research Report is spread
across 95 pages and provides exclusive vital statistics, data,
information, trends and competitive landscape details in this niche
sector.
Development policies and plans are discussed as well as manufacturing
processes and cost structures are also analyzed. This report also
states import/export consumption, supply and demand Figures, cost,
price, revenue and gross margins. The report focuses on global major
leading M-Health Device Industry players providing information such as
company profiles, product picture and specification, capacity,
production, price, cost, revenue and contact information.
The M-Health Device market report is a collection of the first-hand
data, subjective, and quantitative assessment by industry experts and
professionals, contributions from industry specialists and industry
participants over the value chain. The report consists of a detailed
analysis of the industry growth trends, micro- and macroeconomic
components, and governing factors, along with the market attractiveness,
within the market segments. The report likewise maps the subjective
impact of the different market factors on the market segments,
sub-segments, and geographies.
Major Players in M-Health Device Market are: • Allscripts • Apple • Athenahealth • Cerner • Ge Healthcare • Philips • Medtronics
This report includes the estimation of market size for value (million
USD) and volume (K Units). Both top-down and bottom-up approaches have
been used to estimate and validate the market size of M-Health Device
market, to estimate the size of various other dependent submarkets in
the overall market. Key players in the market have been identified
through secondary research, and their market shares have been determined
through primary and secondary research.
All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
Posted by AGORACOM-JC
at 10:15 AM on Thursday, February 20th, 2020
Announced that it is planning a spring drilling campaign as soon as the weather is conducive for entry into the Bonnie Claire Lithium Deposit in Nevada
Iconic has received an update from St-Georges Eco-Mining Corp. regarding Phase 2 metallurgical testing of the lithium-rich sediment from Iconic’s Bonnie Claire lithium deposit in Nevada
Vancouver, British Columbia–(February 20, 2020) – Iconic Minerals Ltd. (TSXV: ICM) (OTC Pink: BVTEF) (FSE: YQGB) (“Company” or “Iconic”) is pleased to announce that it is planning a spring drilling campaign as soon as the weather is conducive for entry into the Bonnie Claire Lithium Deposit in Nevada.
Iconic has received an update from St-Georges Eco-Mining Corp. (“St-George”)
(CSE: SX) regarding Phase 2 metallurgical testing of the lithium-rich
sediment from Iconic’s Bonnie Claire lithium deposit in Nevada. Iconic
is encouraged by this update and is sending additional drill cuttings to
meet St-Georges’ requests and allow further progress toward completing
the Phase 2 report.
St-Georges is proceeding with the next stages of tests within Phase
2, where its current focus is the optimization of chemicals consumption
and purification steps to meet the requirements for lithium hydroxide.
Iconic looks forward to receiving further metallurgical results from St
Georges.
The Bonnie Claire Lithium Property Characteristics:
The Property is located within Sarcobatus Valley that is
approximately 30 km (19 miles) long and 20 km (12 miles) wide.
Quartz-rich volcanic tuffs, that contain anomalous amounts of lithium,
occur within and adjacent to the valley. Geochemical analysis of the
local salt flats has yielded lithium values up to 340 ppm. The gravity
low within the valley is 20 km (12 miles) long, and the current
estimates of depth to basement rocks range from 600 to 1,200 meters
(2,000 to 4,000 feet). The current claim block covers an area of 35 km2
(13.5 mi2) with potential to be underlain by lithium-rich sediments.
On behalf of the Board of Directors
SIGNED: “Richard Kern“
Richard Kern, President and CEO Contact: Keturah Nathe, VP Corporate Development (604) 336-8614
For further information on ICM, please visit our website at www.iconicminerals.com The Company’s public documents may be accessed at www.sedar.com
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of this
release.
Proprietary technology platforms including Electronic Health Records portal and e-Commerce for CBD product distribution
Recently launched CBD extraction facility
First extraction system capacity = 2,300 Kg per year.
CBD based products are poised to be a $20B global industry by 2022
Medical cannabis is poised to be a $100B global industry by 2025
Cannabis Extraction Stocks Best Profit Play for Marijuana Investors
Cannabis Extraction Stocks on Pace for Massive Growth
Cannabis extraction companies are at the center of the hottest trend to hit the legal cannabis industry in years: marijuana derivatives
Those include cannabis-infused products like edibles, vapes, concentrates, beverages, tinctures, and topicals.
By John Whitefoot, BA
In the lead-up to the October 2018 legalization of recreational cannabis in Canada, all eyes were on marijuana growers. It made sense. They were the companies that were going to supply the industry with dried flower. And demand for weed was expected to go through the roof.
While 2019 was a tough year for some pot stocks, 2020 is shaping up
to be much better. Not all pot stocks are created equal though. One area
that looks like it’s poised to outstrip the broader weed stock market
is cannabis extraction stocks.
In 2019, global pot sales soared 48% year-over-year to $15.0 billion.
In 2020, marijuana sales are expected to climb 38%. By 2024, global
weed sales are projected to top $43.0 billion. (Source: “Global Cannabis Sales Grow 48% to $15 Billion in 2019,†BDS Analytics, January 16, 2020.)
A compound annual growth rate of 23% is pretty hard to dismiss.
Legal marijuana is a young industry that is providing investors with a
lot of choices. In addition to the marijuana producers, there are
companies that serve or support those producers—with elements such as
hydroponics, processing, extraction, financing, set-up, e-commerce, and
operating dispensaries.
So far they have mostly been serving the relatively small Canadian
market (Canada has a population less than that of California)—one that,
as of September 2019, had yet to generate $1.0 billion in annual legal
pot sales. (Source: “The Retail Cannabis Market in Canada: A Portrait of the First Year,†Statistics Canada, Statistics Canada, December 11, 2019.)
That number will likely jump considerably once the Canadian marijuana
market matures. Investors who do not want to wait for that to happen,
however, might want to consider cannabis extraction stocks.
Why? Cannabis extraction companies are at the center of the hottest
trend to hit the legal cannabis industry in years: marijuana
derivatives. Those include cannabis-infused products like edibles,
vapes, concentrates, beverages, tinctures, and topicals.
Cannabis-Infused Products Are Crucial for the Pot Industry
Cannabis-infused products are opening up a whole new revenue stream
for the legal marijuana industry. That’s because these items are being
introduced to consumers who may have been reluctant to try traditional
cannabis products. Some people like the buzz or the medicinal properties
but don’t want to inhale smoke.
That is a godsend for marijuana companies looking to juice their top
and bottom lines. That’s because cannabis-infused products have higher
margins than traditional dried cannabis does.
Providing products that have high demand and a high profit margin is a no-brainer.
Cannabis Extract Industry Will Be Huge
In January 2020, cannabis-infused products legally hit store shelves
in Canada for the first time. That came just a year after the Canadian
government approved the sale of recreational marijuana in the form of
dried flower, oils, and sprays.
The cannabis extraction industry will be massive, because the sales projections for pot-infused products are huge.
According to one study, the total legal marijuana market in Canada
will reach $11.0 billion by 2025. Of that, 54% is expected to come from
sales of edibles and other cannabis-extract products. (Source: “One-in-five Canadians will consume cannabis in 2025: Ernst & Young,†Yahoo! Finance Canada, March 26, 2019.)
Now, many cannabis companies do not have in-house extraction
facilities. To make marijuana-infused products, they need to outsource
the work. That’s where cannabis extraction companies come into play.
Instead of growing marijuana, they take hemp and cannabis biomass and
process it for the resins, concentrates, distillates, and targeted
cannabinoids.
Admittedly, some of the bigger licensed marijuana growers in Canada
already have—or are constructing—their own extraction facilities, but it
won’t be enough to meet the future demand for cannabis oils.
In fact, some cannabis growers have signed multi-year, renewable
extraction agreements with the bigger cannabis extraction companies in
Canada.
Analyst Take
Cannabis extraction stocks could be a huge profit opportunity for
marijuana investors. Marijuana-infused products became legal in Canada
at the start of 2020, and the industry is expected to experience
double-digit growth over the coming years.
Thanks to higher margins, more and more companies are looking to
produce cannabis-infused products. If marijuana-derivative products sell
well, cannabis extract stocks should rise in value.
Tags: CSE, Hemp, Marijuana, stocks, tsx Posted in Empower Clinics Inc. | Comments Off on Empower Clinics $CBDT.ca – #Cannabis Extraction Stocks Best Profit Play for #Marijuana Investors $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca
